Skip to content
How It Works
Explore
Resources Ask a Question
Who It's For
Patients
Decode results, prep for appointments, weigh options.
Caregivers & advocates
Carry the research load for someone you love.
Providers & clinicians
Resources for patients in your practice.
Log In Ask a Question
PubMed This is a summary of 19 peer-reviewed journal articles Updated
Ophthalmology

Standard of Care: The Treatment Step-Ladder

At a Glance

Uveitis treatment uses a step-ladder approach to stop inflammation and preserve vision. Doctors usually start with fast-acting corticosteroids, then move to steroid-sparing immunosuppressants or targeted biologics to control chronic disease and avoid long-term steroid side effects.

The goal of uveitis treatment is two-fold: to quickly stop the inflammation that threatens your sight and to find a long-term management plan that has the fewest side effects [1]. Doctors typically use a step-ladder approach, starting with fast-acting medications and moving to more specialized therapies if the condition is chronic or severe [2][3].

Step 1: Corticosteroids & Symptom Control (The First Line)

Corticosteroids are powerful anti-inflammatory drugs that act like a “fire extinguisher” for the eye. They can be delivered in several ways:

  • Topical Drops: Used primarily for Anterior Uveitis [4]. Practical tip: When taking frequent drops, press gently on the inner corner of your eye near the tear duct for a minute (punctal occlusion). This helps the medicine stay in the eye and reduces systemic absorption.
  • Dilating Drops (Cycloplegics): Often prescribed alongside steroids for anterior uveitis. These temporarily paralyze the eye muscle, which significantly relieves deep eye pain and prevents the iris from sticking to the lens (synechiae).
  • Injections and Implants: For inflammation in the middle or back of the eye, doctors may use injections (periocular) or long-term implants like YUTIQ (fluocinolone acetonide). These implants can release medicine for up to three years [5][6].
  • Oral Pills: Used for severe cases or when both eyes are affected.

The “Steroid Trade-off”: While steroids are effective, they are rarely a safe long-term solution because of two major side effects:

  1. Cataracts: Long-term use almost always leads to a clouding of the eye’s natural lens, which may eventually require surgery [7][8].
  2. Ocular Hypertension (IOP Spikes): In many patients (known as “steroid responders”), steroids cause the pressure inside the eye to rise, which can lead to permanent damage called glaucoma [9][10].

Step 2: Steroid-Sparing Immunosuppressants

If your uveitis returns every time you try to lower your steroid dose, or if the side effects are too great, your doctor will move to steroid-sparing agents [11]. These medications calm the immune system more broadly and include:

  • Methotrexate
  • Mycophenolate Mofetil (CellCept)

Important Safety Warning: These medications suppress your systemic immune system, making you more vulnerable to infections. You must promptly report any signs of infection (like fever or chills) to your care team. Additionally, medications like Methotrexate and CellCept can cause severe birth defects (teratogenicity); they require strict birth control and family planning discussions with your doctor [11].

Step 3: Biologics (Targeted Therapy)

Biologics are modern, highly targeted medications that block specific “messenger” chemicals (cytokines) that cause inflammation [12].

  • TNF-Inhibitors: Adalimumab (Humira) and Infliximab (Remicade) are the most common. Adalimumab is often recommended for chronic non-infectious uveitis because it is highly effective at preventing flares and preserving vision [13][14].
  • IL-6 Inhibitors: Medications like Tocilizumab may be used if other biologics fail [15].
    (Note: Like Step 2 medications, Biologics also suppress your immune system and require vigilance for systemic infections).

A Note on Infectious Uveitis

The treatment “ladder” described above is only for non-infectious (autoimmune) uveitis. If your uveitis is caused by an infection—such as Herpes, Toxoplasmosis, or Syphilis—the treatment is completely different [16].

In these cases, the doctor must prescribe antimicrobials or antiviral medications (like Valacyclovir or specific antibiotics) to kill the invader [17]. Using steroids alone on an infection can be dangerous, as it may “mask” the symptoms while the infection grows worse [18][19]. Always ensure your doctor has ruled out infection before starting long-term immune suppression.

Common questions in this guide

What does it mean to be a 'steroid responder' in uveitis treatment?
A steroid responder is a patient whose eye pressure rises significantly when using corticosteroid medications. This increase in pressure, known as ocular hypertension, can lead to permanent damage like glaucoma, so doctors carefully monitor eye pressure during steroid treatment.
What are the side effects of using steroid eye drops long-term?
Long-term use of eye steroids frequently leads to cataracts, which is a clouding of the eye's natural lens. They can also cause dangerous spikes in eye pressure that may result in glaucoma. Because of these risks, steroids are rarely used as a permanent solution.
When will my doctor prescribe a steroid-sparing immunosuppressant?
Doctors switch to steroid-sparing medications, such as methotrexate or CellCept, when uveitis returns every time steroid doses are lowered, or when steroid side effects become too severe. These drugs calm the immune system more broadly without the specific eye risks of steroids.
Why might I need a biologic medication like Humira for uveitis?
Biologics are modern, targeted medications that block specific chemical messengers causing inflammation. Drugs like Humira are prescribed for chronic, non-infectious uveitis when other treatments fail, as they are highly effective at preventing flare-ups and preserving vision.
How is infectious uveitis treated differently than autoimmune uveitis?
If your uveitis is caused by an infection like herpes or syphilis, you must be treated with specific antiviral or antibiotic medications. Using steroids alone for an infection is dangerous because it can mask your symptoms while allowing the infection to grow worse.

Questions to Ask Your Doctor

Curated prompts to bring to your next appointment.

  1. 1.Am I currently a 'steroid responder,' and how often will you be checking my eye pressure (IOP) while I am on this treatment?
  2. 2.At what point should we consider moving from steroids to a 'steroid-sparing' agent like Methotrexate or Mycophenolate?
  3. 3.If I need an implant like YUTIQ, what is my specific risk of developing a cataract or needing glaucoma surgery later?
  4. 4.Is my uveitis severe enough that we should discuss starting a biologic like Humira (adalimumab) now rather than waiting?
  5. 5.If we suspect an infection, what tests will you run to ensure I receive the correct antiviral or antibiotic therapy before we use steroids?

Questions For You

Tap a prompt to share your answer — we'll use it plus this page's context to start a tailored conversation.

References

References (19)
  1. 1

    Behçet's Disease Uveitis.

    Joubert M, Desbois AC, Domont F, et al.

    Journal of clinical medicine 2023; (12(11)) doi:10.3390/jcm12113648.

    PMID: 37297843
  2. 2

    Pediatric uveitis: A comprehensive review.

    Maleki A, Anesi SD, Look-Why S, et al.

    Survey of ophthalmology 2022; (67(2)):510-529 doi:10.1016/j.survophthal.2021.06.006.

    PMID: 34181974
  3. 3

    Retrospective Study Evaluating Treatment Decisions and Outcomes of Childhood Uveitis Not Associated with Juvenile Idiopathic Arthritis.

    Sardar E, Dusser P, Rousseau A, et al.

    The Journal of pediatrics 2017; (186()):131-137.e1 doi:10.1016/j.jpeds.2017.03.052.

    PMID: 28457525
  4. 4

    Management of Acute Non-Infectious Anterior Uveitis in Adults - Practice Patterns Among Uveitis Specialists in North America.

    Zhang H, Nicholson CM, Kempen JH, et al.

    Ocular immunology and inflammation 2025; (33(7)):1153-1158 doi:10.1080/09273948.2024.2346819.

    PMID: 38749068
  5. 5

    Preliminary evaluation of YUTIQ™ (fluocinolone acetonide intravitreal implant 0.18 mg) in posterior uveitis.

    Testi I, Pavesio C

    Therapeutic delivery 2019; (10(10)):621-625 doi:10.4155/tde-2019-0051.

    PMID: 31663454
  6. 6

    Long-Acting Fluocinolone Acetonide Intravitreal Implant for Recurrent Bilateral Non-Infectious Posterior Uveitis.

    Babel AT, Chin EK, Almeida DRP

    International medical case reports journal 2022; (15()):665-669 doi:10.2147/IMCRJ.S384356.

    PMID: 36444172
  7. 7

    Steroid Induced Cataract in Langerhans Cell Histiocytosis Patient.

    Sutyawan WE, Widiastuti IAP, Ryalino C

    Open access Macedonian journal of medical sciences 2019; (7(6)):1025-1028 doi:10.3889/oamjms.2019.233.

    PMID: 30976354
  8. 8

    Quality of Life and Risks Associated with Systemic Anti-inflammatory Therapy versus Fluocinolone Acetonide Intraocular Implant for Intermediate Uveitis, Posterior Uveitis, or Panuveitis: Fifty-four-Month Results of the Multicenter Uveitis Steroid Treatment Trial and Follow-up Study.

    Ophthalmology 2015; (122(10)):1976-86.

    PMID: 26298718
  9. 9

    Steroid-induced glaucoma in the pediatric population.

    Nuyen B, Weinreb RN, Robbins SL

    Journal of AAPOS : the official publication of the American Association for Pediatric Ophthalmology and Strabismus 2017; (21(1)):1-6 doi:10.1016/j.jaapos.2016.09.026.

    PMID: 28087345
  10. 10

    Risk of Elevated Intraocular Pressure With Difluprednate in Patients With Non-Infectious Uveitis.

    Yakin M, Kumar A, Kodati S, et al.

    American journal of ophthalmology 2022; (240()):232-238 doi:10.1016/j.ajo.2022.03.026.

    PMID: 35381204
  11. 11

    Long-Term Outcomes of Treatment with Biological Agents in Eyes with Refractory, Active, Noninfectious Intermediate Uveitis, Posterior Uveitis, or Panuveitis.

    Al-Janabi A, El Nokrashy A, Sharief L, et al.

    Ophthalmology 2020; (127(3)):410-416 doi:10.1016/j.ophtha.2019.08.031.

    PMID: 31607412
  12. 12

    Real-World outcomes of adalimumab in adults with non-infectious uveitis.

    Leal I, Wong SW, Giuffre C, et al.

    Acta ophthalmologica 2022; (100(7)):e1496-e1502 doi:10.1111/aos.15120.

    PMID: 35277918
  13. 13

    Adalimumab in patients with vision-threatening uveitis: real-world clinical experience.

    Tang Lee Say TL, Yang V, Fingret JM, et al.

    BMJ open ophthalmology 2021; (6(1)):e000819 doi:10.1136/bmjophth-2021-000819.

    PMID: 34632076
  14. 14

    Effectiveness and Safety of Anti-Tumor Necrosis Factor-Alpha Agents Treatment in Behcets' Disease-Associated Uveitis: A Systematic Review and Meta-Analysis.

    Hu Y, Huang Z, Yang S, et al.

    Frontiers in pharmacology 2020; (11()):941 doi:10.3389/fphar.2020.00941.

    PMID: 32670062
  15. 15

    Evolving landscape of small-molecule immunotherapeutics for uveitis: a scoping review.

    Yim TSY, Cifuentes-González C, Agrawal R, Oon HH

    Drug discovery today 2025; (30(12)):104515 doi:10.1016/j.drudis.2025.104515.

    PMID: 41161567
  16. 16

    Ocular Syphilis: The Resurgence of an Old Disease Experience of a Tertiary Centre in Portugal.

    Costa C, Machado T, Zhu A, et al.

    Ocular immunology and inflammation 2025; (33(3)):385-395 doi:10.1080/09273948.2024.2413902.

    PMID: 39388630
  17. 17

    Varicella zoster virus cerebral aneurysmal vasculopathy presenting in a newly-diagnosed HIV-positive patient.

    Tomkins A, Babu C, Herwadkar A, et al.

    International journal of STD & AIDS 2018; (29(13)):1351-1353 doi:10.1177/0956462418786334.

    PMID: 30049255
  18. 18

    The Role of Corticosteroids in Treating Acute Ocular Toxoplasmosis in an Immunocompetent Patient: A Case Report.

    Lin HY, Lee WA

    Frontiers in medicine 2022; (9()):843050 doi:10.3389/fmed.2022.843050.

    PMID: 35847774
  19. 19

    A typical Vitelliform-Like Maculopathy Secondary to Bartonella henselae Neuroretinitis.

    Illiano W, Crosson J

    Journal of vitreoretinal diseases 2026; 24741264261418514 doi:10.1177/24741264261418514.

    PMID: 41727755

This page explains uveitis treatment options for educational purposes only. Always consult your ophthalmologist or rheumatologist before starting, stopping, or changing any prescribed eye medications.

Get notified when new evidence is published on Uveitis.

We monitor PubMed for new peer-reviewed studies on this topic and email a short summary when something meaningful changes.